Company
Overview
For Investors
News
Team
Executive Board
Management Team
Scientific Advisory Board
Pertussis
Whooping Cough
B. pertussis
Bacteria
Treatment vs Prevention
Subclinical Colonization + Transmission
Adult/adolescent Boosters
Our Science
BPZE1 Vaccine
Why a Live Vaccine?
Preventing Colonization + Transmission
Preclinical Safety
BPZE1 Publications
Disease Science
- Alzheimer’s Disease
- Allergic Disease
- Autoimmune Disease
Clinical
Opportunity
Market
Pipeline
Intellectual Property
B-Tech
Targeting Disease
with
B-Tech
B-Tech
Vector Platform
Vaccine Candidates
B. Pertussis
Disease Research
BioLyo Tech
Contact
Team
Executive Board
Management Team
Scientific Advisory Board
Join Our Mailing List
Management Team
Keith Rubin, M.D.
Founder and Chief Executive Officer
Ken Solovay
Chief Operating Officer
Stephanie Noviello, M.D., M.P.H.
Chief Medical Officer
Luis Rios-Nogales, M.D., Ph.D., M.B.A.
Executive VP and Chief Development Officer
Amy Fix
Chief Regulatory Officer
Alex Durso
Executive Vice-President, Quality
André Morais Campos
Vice-President, Global Clinical Operations
Marcel Thalen, Ph.D.
Vice-President, Drug Product Development
Stanley Kim, Ph.D., Esq.
Senior Vice President, Intellectual Property and Contracts
Vivek Samal, M.B., B.S., M.D.
Executive Medical Director, Vaccine Safety
Peter Goldstein
Executive Director, Research and Development
Ana Keiko Sekine
Executive Director, Global Clinical Operations.
David Hinkel
Executive Director, Supply Chain Operations
Karen Salovich
Senior Director of Regulatory Operations
Luciana da Silva Meira Butera
Associate Manager, Clinical Process Excellence
Theressa Creighton
Associate Director, Clinical Operations
Steve Glazer, M.D.
Director, New Research Programs
Jim Ramadei
Controller
Matthew Bross
Administrative Manager
Copyright 2013-2024 ILiAD Biotechnologies